Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation-Reference-Cited by-同舟云学术

Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation

Published:2016-07-05 Issue:3 Volume:175 Page:440-447
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Shah Gunjan L.¹^ORCID,Yahalom Joachim²,Matasar Matthew J.¹³,Verwys Stephanie L.³,Goldman Debra A.⁴,Bantilan Kurt S.³,Zhang Zhigang⁴,McCall Susan J.³,Moskowitz Alison J.³,Moskowitz Craig H.¹³

Affiliation:

1. Department of Medicine; Adult Bone Marrow Transplant Service; Memorial Sloan Kettering Cancer Center; New York NY USA

2. Department of Radiation Oncology; Memorial Sloan Kettering Cancer Center; New York NY USA

3. Department of Medicine; Lymphoma Service; Memorial Sloan Kettering Cancer Center; New York NY USA

4. Department of Epidemiology-Biostatistics; Memorial Sloan Kettering Cancer Center; New York NY USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14245/fullpdf

Reference22 articles.

1. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT;Akhtar;Bone Marrow Transplantation,2013

2. Phase I/II Trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma;Arai;Biology of Blood and Marrow Transplantation,2010

3. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant;Arai;Leukemia & Lymphoma,2013

4. Risk factors and a prognostic score for progression free survival after treatment with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory hodgkin lymphoma (rrHL);Bröckelmann;In Blood (ASH Annual Meeting Abstracts),2015

5. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy;Castagna;British Journal of Haematology,2009

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies;Leukemia & Lymphoma;2024-01-02

2. Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era;Blood Advances;2023-12-01

3. Hodgkin lymphoma: Focus on evolving treatment paradigms;Best Practice & Research Clinical Haematology;2023-12

4. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant;Transplantation and Cellular Therapy;2023-07

5. Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma;American Journal of Hematology;2023-01-11